Congress orders lung cancer research review for women, underserved groups
S. 1157 — Women and Lung Cancer Research and Preventive Services Act of 2025 · Filed by Tina Smith (D-MN) · 7 cosponsors · Introduced Mar 26, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services, working with the Defense and Veterans Affairs departments, to review federal lung cancer research and prevention programs—particularly for women and underserved populations—and identify gaps in knowledge and screening rates. The Secretary must report back to Congress within two years with findings, any changes made to federal programs, and recommendations for further improvements.
Why we flagged it
The bill's operative mechanism is a federal interagency review and reporting requirement focused on identifying research gaps and improving lung cancer outcomes in women and underserved populations. It is a straightforward public health investigation tool with no private carve-outs or immunity grants.
What the text implies
- The review may identify funding gaps or unmet research needs, potentially creating pressure for future appropriations or reallocation of existing research budgets to lung cancer programs.
- Emphasis on 'populations with few known risk factors' and environmental/genomic factors may shift research focus toward non-smoking-related lung cancer, potentially affecting how prevention messaging is framed.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical companies developing lung cancer treatments and biomarker tests; medical device manufacturers producing screening and diagnostic equipment; research institutions and universities receiving federal lung cancer research funding